Indietro

Novartis AG ADR

Ticker: NVS ISIN: US66987V1098
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Capitalizzazione
221,49 Mld $
P/E
19,14
Forward P/E
13,61
Profit margin
23,09%
Revenue growth QoQ
15,10%
Div. yield
3,56%
Beta
0,55
159,98 $ 1,24%
Prezzo al 2026-08-25 · NYSE

Performance per periodo

Rendimenti cumulativi
1 Month +2,48%
6 Months -1,20%
1 Year +30,17%
5 Years +15,97% p.a.+109,64%
10 Years +12,45% p.a.+223,17%
Since inception +10,20% p.a.+1.029,92%
Rendimenti per anno
YTD +19,57%
2025 +46,95%
2024 +0,02%
2023 +16,14%
2022 +8,06%
2021 -3,65%

Key stats

Market cap
221,49 Mld
P/E
19,14
Dividend yield
3,56%
Beta
0,55
52-week range
92.72 - 116.72
50-day MA
109,72
200-day MA
108,92
Section 1

Business overview

Company profile data from fundamentals.

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sector Healthcare
Industry Drug Manufacturers - General
Country Switzerland
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 26,28%
ROA 10,09%
Profit margin 23,09%
Operating margin 29,94%
PEG ratio 1,30
Revenue/share TTM 25,63
Revenue TTM 51,72 Mld
EBITDA 20,66 Mld
Gross profit TTM 38,91 Mld
Beta 0,55

Valuation

Trailing P/E 19,14
Forward P/E 13,61
P/B 5,03
P/S 4,28
EV/EBITDA 11,49
EV/Revenue 4,60
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 8,62
Quarterly earnings growth -65,60%
Revenue TTM 51,72 Mld
Reported quarters 99
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 3,56%
Forward annual div. yield 3,56%
Dividend per share 3,8620
Payout ratio 51,14%
Ex-dividend date 2025-03-12
Split factor 1116:1000
Last split date 2019-04-09
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 112,26 $
Analyst rating 2.8462

Ownership & short interest

Shares outstanding 1,98 Mld
Shares float 1,88 Mld
Institutional ownership 6,71%
Insider ownership 0,30%
Short ratio 1,27
Short % of float 0,16%

Details

Instrument metadata and source update timestamps.

Symbol NVS
Name Novartis AG ADR
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US66987V1098
Country USA
Code + exchange NVS.NYSE
Last price date 2025-04-25
Fundamentals updated 2025-04-26

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.